Hemoptysis and Behçet's Syndrome

ADRIAN F. PEALL, BM, MRCP, Specialist Registrar; SHARON M. JONES, MD, FRCP, Consultant Rheumatologist, Rheumatology Department, University Hospital Wales, Heath Park, Cardiff, CF14 4XN, UK. Address reprint requests to Dr. Peall. E-mail: adrianpeall@yahoo.co.uk
J Rheumatol 2009;36:848–9; doi:10.3899/jrheum.080900

Pulmonary aneurysms associated with Behçet's syndrome typically affect young men and carry a high mortality of 30% within 2 years of diagnosis^{1,2}. A 27-year-old man with a history of Behçet's syndrome was admitted to our hospital with an episode of large-volume hemoptysis.

The syndrome had originally manifested with severe ophthalmic involvement leading to visual loss. He had initially been managed with high-dose steroids and mycophenolate mofetil, but had stopped attending clinic 18 months prior to this emergency admission and had not continued taking any immunosuppression.

The plain chest radiograph from his admission showed a rounded opacity in the right lower zone (Figure 1, arrow). The corresponding computed tomography (CT) image of the thorax confirmed a partially thrombosed pulmonary artery aneurysm in this region (Figure 2, arrow); a smaller aneurysm is also visible in the left lower lobe (Figure 2, arrow). A coronal image shows the relationship between the large right-side aneurysm and its accompanying arterial supply (Figure 3).

Our patient was treated with high-dose intravenous steroids and cyclophosphamide, as well as radiologically guided embolization of the aneurysm. To date, he has made a good recovery.

The combination of embolization and immunosuppression is reported as giving the best chance of recovery of current treatment strategies for pulmonary aneurysms associated with Behçet's syndrome³. Surgical intervention can be necessary for urgent treatment, but is associated with recurrence at the operative site. Anti-tumor necrosis factor is recommended for other complications of Behçet's, especially for eye involvement⁴. Evidence of usage for pulmonary artery aneurysms is limited at present⁵, but may represent a potential for future management of this severe life-threatening complication.

REFERENCES

1. Raz I, Okon E, Chajek-Shoul T. Pulmonary manifestations in Behçet's syndrome. *Chest* 1989;95:585-9.
2. Tunaci M, Ozkokmaz B, Tunaci A, et al. CT findings of pulmonary artery aneurysms during treatment for Behçet's disease. *AJR Am*

Figure 1. Plain chest radiograph shows rounded opacity in the right lower zone (arrow).

Figure 2. CT angiography of the thorax shows a large right-side, partially thrombosed pulmonary artery aneurysm (arrow); a smaller partially thrombosed aneurysm in the left lower is also visible (arrow).

Figure 3. CT angiography of the thorax shows the relationship between the large right-side aneurysm and its accompanying arterial supply.

- J Roentgenol 1999;172:729-33.
3. Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in Behcet's disease: a cumulative analysis. Chest 2005;127:2243-53.
4. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease — review and basis for recommendations. Rheumatology Oxford 2007;46:736-41.
5. Baki K, Villiger PM, Jenni D, Meyer T, Beer JH. Behcet's disease with life threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab. Ann Rheum Dis 2006;65:1531-2.